Skip to main content
Top
Published in: Breast Cancer Research 6/2003

Open Access 01-12-2003 | Research article

Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA)

Authors: Carmel Apicella, Lesley Andrews, Shirley V Hodgson, Sheila A Fisher, Cathryn M Lewis, Ellen Solomon, Katherine Tucker, Michael Friedlander, Agnes Bankier, Melissa C Southey, Deon J Venter, John L Hopper

Published in: Breast Cancer Research | Issue 6/2003

Login to get access

Abstract

Introduction

Ancestral mutations in BRCA1 and BRCA2 are common in people of Ashkenazi Jewish descent and are associated with a substantially increased risk of breast and ovarian cancer. Women considering mutation testing usually have several personal and family cancer characteristics, so predicting mutation status from one factor alone could be misleading. The aim of this study was to develop a simple algorithm to estimate the probability that an Ashkenazi Jewish woman carries an ancestral mutation, based on multiple predictive factors.

Methods

We studied Ashkenazi Jewish women with a personal or family history of breast or ovarian cancer and living in Melbourne or Sydney, Australia, or with a previous diagnosis of breast or ovarian cancer and living in the UK. DNA samples were tested for the germline mutations 185delAG and 5382insC in BRCA1, and 6174delT in BRCA2. Logistic regression was used to identify, and to estimate the predictive strength of, major determinants.

Results

A mutation was detected in 64 of 424 women. An algorithm was developed by combining our findings with those from similar analyses of a large study of unaffected Jewish women in Washington. Starting with a baseline score, a multiple of 0.5 (based on the logistic regression estimates) is added for each predictive feature. The sum is the estimated log odds ratio that a woman is a carrier, and is converted to a probability by using a table. There was good internal consistency.

Conclusions

This simple algorithm might be useful in the clinical and genetic counselling setting. Comparison and validation in other settings should be sought.
Literature
1.
go back to reference Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997, 336: 1401-1408. 10.1056/NEJM199705153362001.CrossRefPubMed Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997, 336: 1401-1408. 10.1056/NEJM199705153362001.CrossRefPubMed
2.
go back to reference Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB: The lifetime risks of breast cancer in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomark Prevent. 2001, 10: 467-473. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB: The lifetime risks of breast cancer in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomark Prevent. 2001, 10: 467-473.
3.
go back to reference Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999, 64: 963-970. 10.1086/302320.CrossRefPubMedPubMedCentral Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999, 64: 963-970. 10.1086/302320.CrossRefPubMedPubMedCentral
4.
go back to reference Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, Haas B, Osborne M, Norton L, Gilbert F, Offit K: Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test. 1997, 1: 47-51.PubMed Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, Haas B, Osborne M, Norton L, Gilbert F, Offit K: Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test. 1997, 1: 47-51.PubMed
5.
go back to reference Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998, 63: 45-51. 10.1086/301903.CrossRefPubMedPubMedCentral Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998, 63: 45-51. 10.1086/301903.CrossRefPubMedPubMedCentral
6.
go back to reference Fitzgerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996, 334: 143-149. 10.1056/NEJM199601183340302.CrossRefPubMed Fitzgerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996, 334: 143-149. 10.1056/NEJM199601183340302.CrossRefPubMed
7.
go back to reference Moslehi R, Chu W, Karlan B, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 2000, 66: 1259-1272. 10.1086/302853.CrossRefPubMedPubMedCentral Moslehi R, Chu W, Karlan B, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 2000, 66: 1259-1272. 10.1086/302853.CrossRefPubMedPubMedCentral
8.
go back to reference Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997, 60: 1059-1067.PubMedPubMedCentral Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997, 60: 1059-1067.PubMedPubMedCentral
9.
go back to reference Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997, 60: 505-514.PubMedPubMedCentral Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997, 60: 505-514.PubMedPubMedCentral
10.
go back to reference Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999, 91: 1241-1247. 10.1093/jnci/91.14.1241.CrossRefPubMed Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999, 91: 1241-1247. 10.1093/jnci/91.14.1241.CrossRefPubMed
11.
go back to reference Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Thomas A: BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997, 278: 1242-1250. 10.1001/jama.278.15.1242.CrossRefPubMed Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Thomas A: BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997, 278: 1242-1250. 10.1001/jama.278.15.1242.CrossRefPubMed
12.
go back to reference Couch FJ, DeShano ML, Blackwood A, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997, 336: 1409-1415. 10.1056/NEJM199705153362002.CrossRefPubMed Couch FJ, DeShano ML, Blackwood A, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997, 336: 1409-1415. 10.1056/NEJM199705153362002.CrossRefPubMed
13.
go back to reference Hopper JL, Jenkins MA: Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2. Am J Hum Genet. 1999, 65: 1771-1775. 10.1086/302674.CrossRefPubMedPubMedCentral Hopper JL, Jenkins MA: Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2. Am J Hum Genet. 1999, 65: 1771-1775. 10.1086/302674.CrossRefPubMedPubMedCentral
14.
go back to reference Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, Solomon E, Lewis CM: Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J Med Genet. 1999, 36: 369-373.PubMedPubMedCentral Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, Solomon E, Lewis CM: Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J Med Genet. 1999, 36: 369-373.PubMedPubMedCentral
15.
go back to reference Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL: Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001, 19: 2247-2253.CrossRefPubMed Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL: Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001, 19: 2247-2253.CrossRefPubMed
16.
go back to reference Foulkes WD, Brunet JS, Warner E, Goodwin PJ, Meschino W, Narod SA, Goss PE, Glendon G: The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet. 1999, 65: 1776-1779. 10.1086/302675.CrossRefPubMedPubMedCentral Foulkes WD, Brunet JS, Warner E, Goodwin PJ, Meschino W, Narod SA, Goss PE, Glendon G: The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet. 1999, 65: 1776-1779. 10.1086/302675.CrossRefPubMedPubMedCentral
17.
go back to reference Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG: Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr. 1999, 26: 95-100.CrossRef Hopper JL, Chenevix-Trench G, Jolley DJ, Dite GS, Jenkins MA, Venter DJ, McCredie MR, Giles GG: Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS). J Natl Cancer Inst Monogr. 1999, 26: 95-100.CrossRef
18.
go back to reference Southey MC, Tesoriero AA, Anderson CR, Jennings KM, Brown SM, Dite GS, Jenkins MA, Osborne RH, Maskiell JA, Porter L, Giles GG, McCredie MR, Hopper JL, Venter DJ: BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer. 1999, 79: 34-39. 10.1038/sj.bjc.6690008.CrossRefPubMedPubMedCentral Southey MC, Tesoriero AA, Anderson CR, Jennings KM, Brown SM, Dite GS, Jenkins MA, Osborne RH, Maskiell JA, Porter L, Giles GG, McCredie MR, Hopper JL, Venter DJ: BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer. 1999, 79: 34-39. 10.1038/sj.bjc.6690008.CrossRefPubMedPubMedCentral
19.
go back to reference Baker RJ, Nelder JA: The GLIM System, Release 3: Generalized Linear Interactive Modelling. Oxford: Numerical Algorithms Group. 1978 Baker RJ, Nelder JA: The GLIM System, Release 3: Generalized Linear Interactive Modelling. Oxford: Numerical Algorithms Group. 1978
20.
go back to reference Cox DR, Snell EJ: Analysis of Binary Data. London: Chapman & Hall. 1989, 41-43. 2 Cox DR, Snell EJ: Analysis of Binary Data. London: Chapman & Hall. 1989, 41-43. 2
21.
go back to reference Wacholder S, Hartge P: Response to the letters from Hopper and Jenkins and Foulkes et al. Am J Hum Genet. 1999, 65: 1775-1776. 10.1086/302688.CrossRefPubMedCentral Wacholder S, Hartge P: Response to the letters from Hopper and Jenkins and Foulkes et al. Am J Hum Genet. 1999, 65: 1775-1776. 10.1086/302688.CrossRefPubMedCentral
22.
go back to reference Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998, 62: 145-158. 10.1086/301670.CrossRefPubMedPubMedCentral Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998, 62: 145-158. 10.1086/301670.CrossRefPubMedPubMedCentral
23.
go back to reference Peto J, Collins N, Barfoot R, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.CrossRefPubMed Peto J, Collins N, Barfoot R, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.CrossRefPubMed
24.
go back to reference Antoniou AC, Pharoah PDP, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DFA: Comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002, 86: 76-83. 10.1038/sj.bjc.6600008.CrossRefPubMedPubMedCentral Antoniou AC, Pharoah PDP, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DFA: Comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002, 86: 76-83. 10.1038/sj.bjc.6600008.CrossRefPubMedPubMedCentral
25.
go back to reference Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, Giles GG, McCredie MRE, Hopper JL: After BRCA1 and BRCA2 – what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet. 2001, 68: 420-431. 10.1086/318187.CrossRefPubMed Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, Giles GG, McCredie MRE, Hopper JL: After BRCA1 and BRCA2 – what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet. 2001, 68: 420-431. 10.1086/318187.CrossRefPubMed
26.
go back to reference Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ: Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999, 59: 2011-2017.PubMed Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ: Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999, 59: 2011-2017.PubMed
Metadata
Title
Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA)
Authors
Carmel Apicella
Lesley Andrews
Shirley V Hodgson
Sheila A Fisher
Cathryn M Lewis
Ellen Solomon
Katherine Tucker
Michael Friedlander
Agnes Bankier
Melissa C Southey
Deon J Venter
John L Hopper
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2003
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr644

Other articles of this Issue 6/2003

Breast Cancer Research 6/2003 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine